{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:49:04Z","timestamp":1769755744420,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00549-0","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:06:41Z","timestamp":1754327201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of abatacept in rheumatoid arthritis patients in Western region in Saudi Arabia: a multi-center study"],"prefix":"10.1186","volume":"9","author":[{"given":"Lina S.","family":"Alahmadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaher I.","family":"Alaauldeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand M.","family":"Melibari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman A.","family":"Alsindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem M.","family":"Hafiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara F.","family":"Alqurashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad A.","family":"Alrowithi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala M.","family":"Albuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"549_CR1","unstructured":"Chauhan K, Jandu JS, Brent LH, Al-Dhahir MA. Rheumatoid Arthritis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170:ITC1. https:\/\/doi.org\/10.7326\/AITC201901010.","journal-title":"Ann Intern Med"},{"key":"549_CR3","doi-asserted-by":"publisher","first-page":"CD007277","DOI":"10.1002\/14651858.CD007277.pub2","volume":"2009","author":"L Maxwell","year":"2009","unstructured":"Maxwell L, Singh JA. ABA for RA. Cochrane Database Syst Rev. 2009;2009:CD007277. https:\/\/doi.org\/10.1002\/14651858.CD007277.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"549_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/oarrr.s4536","volume":"1","author":"JR Lutt","year":"2009","unstructured":"Lutt JR. Efficacy, safety, and tolerability of abatacept in the management of RA. Open Access Rheumatol Res Rev. 2009;1:17\u201335. https:\/\/doi.org\/10.2147\/oarrr.s4536.","journal-title":"Open Access Rheumatol Res Rev"},{"key":"549_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","volume":"26","author":"M Harigai","year":"2016","unstructured":"Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with RA. Mod Rheumatol. 2016;26:491\u20138. https:\/\/doi.org\/10.3109\/14397595.2015.1123211.","journal-title":"Mod Rheumatol"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, Double-Blind trial of ABA (CTLA- 4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69:837\u201345. https:\/\/doi.org\/10.1002\/art.40044.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/13543784.2016.1154943","volume":"25","author":"VR Pimentel-Quiroz","year":"2016","unstructured":"Pimentel-Quiroz VR, Ugarte-Gil MF, Alarc\u00f3n GS. ABA for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs. 2016;25:493\u20139. https:\/\/doi.org\/10.1517\/13543784.2016.1154943.","journal-title":"Expert Opin Investig Drugs"},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/acr2.1034","volume":"1","author":"TA Simon","year":"2019","unstructured":"Simon TA, Soule BP, Hochberg M, Fleming D, Torbeyns A, Banerjee S, Boers M. Safety of ABA versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials. ACR Open Rheumatol. 2019;1:251\u20137. https:\/\/doi.org\/10.1002\/acr2.1034.","journal-title":"ACR Open Rheumatol"},{"key":"549_CR9","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2xjg0d","author":"M Mohamed Ahamada","year":"2022","unstructured":"Mohamed Ahamada M, Wu X. Analysis of efficacy and safety of abatacept for RA: systematic review and meta-analysis. Clin Exp Rheumatol Published Online First: 4 Oct. 2022. https:\/\/doi.org\/10.55563\/clinexprheumatol\/2xjg0d.","journal-title":"Clin Exp Rheumatol Published Online First: 4 Oct"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","volume":"21","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, Schumacher R, Simon TA, Michaud K. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with RA: data from an observational study. Arthritis Res Ther. 2019;21:141. https:\/\/doi.org\/10.1186\/s13075-019-1921-z.","journal-title":"Arthritis Res Ther"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in patients with RA. Autoimmun Rev. 2013;12:1115\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2013.06.011.","journal-title":"Autoimmun Rev"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","volume":"21","author":"TA Simon","year":"2019","unstructured":"Simon TA, Boers M, Hochberg M, et al. Comparative risk of malignancies and infections in patients with RA initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res Ther. 2019;21:228. https:\/\/doi.org\/10.1186\/s13075-019-1992-x.","journal-title":"Arthritis Res Ther"},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jsps.2022.04.008","volume":"30","author":"HM Almalag","year":"2022","unstructured":"Almalag HM, Alaujan SS, Alhazzani HS, et al. Prevalence of adverse reactions to intravenously administered originator biologics in patients with RA: A 5-year retrospective study. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2022;30:1044\u201351. https:\/\/doi.org\/10.1016\/j.jsps.2022.04.008.","journal-title":"Saudi Pharm J SPJ Off Publ Saudi Pharm Soc"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s10067-019-04508-2","volume":"38","author":"SH Elmedany","year":"2019","unstructured":"Elmedany SH, Mohamed AE, Galil SMA. Efficacy and safety profile of intravenous Tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to- severe RA. Clin Rheumatol. 2019;38:2109\u201317. https:\/\/doi.org\/10.1007\/s10067-019-04508-2.","journal-title":"Clin Rheumatol"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1756-185X.12659","volume":"19","author":"C Downey","year":"2016","unstructured":"Downey C. Serious infection during etanercept, Infliximab and adalimumab therapy for RA: A literature review. Int J Rheum Dis. 2016;19:536\u201350. https:\/\/doi.org\/10.1111\/1756-185X.12659.","journal-title":"Int J Rheum Dis"},{"key":"549_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3899\/jrheum.100717","volume":"38","author":"JA Singh","year":"2011","unstructured":"Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: A Cochrane systematic review. J Rheumatol. 2011;38:10\u201320. https:\/\/doi.org\/10.3899\/jrheum.100717.","journal-title":"J Rheumatol"},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"549_CR18","unstructured":"WHO. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. 2002. Accessed 26 May 2024. https:\/\/www.who.int\/publications\/i\/item\/WHO-EDM-QSM-2002-2"},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s41927-022-00299-3","volume":"6","author":"HL Pisaniello","year":"2022","unstructured":"Pisaniello HL, Whittle SL, Lester S, et al. Using the derived 28-joint disease activity score patient- reported components (DAS28-P) index as a discriminatory measure of response to disease- modifying anti-rheumatic drug therapy in early RA. BMC Rheumatol. 2022;6:67. https:\/\/doi.org\/10.1186\/s41927-022-00299-3.","journal-title":"BMC Rheumatol"},{"key":"549_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and EULAR response criteria based on C-reactive protein against disease progression in patients with RA, and comparison with the DAS28 based on ESR. Ann Rheum Dis. 2009;68:954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"key":"549_CR21","doi-asserted-by":"publisher","first-page":"e8094","DOI":"10.7759\/cureus.8094","volume":"12","author":"F Angum","year":"2020","unstructured":"Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of autoimmune disorders in women: A narrative review. Cureus. 2020;12:e8094. https:\/\/doi.org\/10.7759\/cureus.8094.","journal-title":"Cureus"},{"key":"549_CR22","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.16.0935","author":"KH \u00d8rstavik","year":"2017","unstructured":"\u00d8rstavik KH. Hvorfor Er autoimmune sykdommer hyppigere Hos kvinner? Tidsskr Den nor legeforening. Published Online First. 2017. https:\/\/doi.org\/10.4045\/tidsskr.16.0935.","journal-title":"Published Online First"},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40695-015-0012-9","volume":"1","author":"W Marder","year":"2015","unstructured":"Marder W, Vinet \u00c9, Somers EC. Rheumatic autoimmune diseases in women and midlife health. Womens Midlife Health. 2015;1:11. https:\/\/doi.org\/10.1186\/s40695-015-0012-9.","journal-title":"Womens Midlife Health"},{"key":"549_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1874192401105010064","volume":"5","author":"TE Toms","year":"2011","unstructured":"Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J. 2011;5:64\u201375. https:\/\/doi.org\/10.2174\/1874192401105010064.","journal-title":"Open Cardiovasc Med J"},{"key":"549_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/RHU.0000000000002013","volume":"29","author":"L Bessette","year":"2023","unstructured":"Bessette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the type of failure and the choice of the second biologic influence response and persistence on medication in rheumatoid arthritis?? JCR J Clin Rheumatol. 2023;29:332\u201340. https:\/\/doi.org\/10.1097\/RHU.0000000000002013.","journal-title":"JCR J Clin Rheumatol"},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"755844","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844. https:\/\/doi.org\/10.3389\/fimmu.2021.755844.","journal-title":"Front Immunol"},{"key":"549_CR27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/acr2.11629","volume":"5","author":"S Aboulenain","year":"2023","unstructured":"Aboulenain S, Li X, Movahedi M, Bombardier C, Kuriya B. Cardiovascular risk factors and the risk of discontinuation of advanced therapies due to treatment failure in rheumatoid arthritis: results from the Ontario best practices research initiative. ACR Open Rheumatol. 2023;5:712\u20137. https:\/\/doi.org\/10.1002\/acr2.11629.","journal-title":"ACR Open Rheumatol"},{"key":"549_CR28","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","volume":"61","author":"NMT Roodenrijs","year":"2022","unstructured":"Roodenrijs NMT, Welsing PMJ, Van Roon J, et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat RA: a narrative review with systematic literature search. Rheumatology. 2022;61:3552\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/keac114.","journal-title":"Rheumatology"},{"key":"549_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s42358-020-00154-4","volume":"60","author":"MA Said","year":"2020","unstructured":"Said MA, Silva LSTE, De Oliveira Rocha AM, Alves GGB, Piotto DGP, Len CA, Terreri MT. Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort. Adv Rheumatol. 2020;60:53. https:\/\/doi.org\/10.1186\/s42358-020-00154-4.","journal-title":"Adv Rheumatol"},{"key":"549_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-023-03067-x","volume":"25","author":"A Dominique","year":"2023","unstructured":"Dominique A, Hetland ML, Finckh A, et al. Safety outcomes in patients with RA treated with abatacept: results from a multinational surveillance study across seven European registries. Arthritis Res Ther. 2023;25:101. https:\/\/doi.org\/10.1186\/s13075-023-03067-x.","journal-title":"Arthritis Res Ther"},{"key":"549_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1759720X09360429","volume":"2","author":"R Westhovens","year":"2010","unstructured":"Westhovens R, Verschueren P. The efficacy and safety of abatacept in RA. Ther Adv Musculoskelet Dis. 2010;2:89\u201394. https:\/\/doi.org\/10.1177\/1759720X09360429.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"549_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1093\/mr\/roab029","volume":"32","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Matsubara T, Hashizume K, Amano N, Takeuchi T. Efficacy and safety of abatacept in biologic-na\u00efve patients with active RA by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. Mod Rheumatol. 2022;32:500\u20137. https:\/\/doi.org\/10.1093\/mr\/roab029.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"549_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/ard-2023-224437","volume":"83","author":"JS Smolen","year":"2024","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of RA with synthetic and biological disease-modifying antirheumatic drugs: 2023 update. Ann Rheum Dis. 2024;83(3):313\u201328. https:\/\/doi.org\/10.1136\/ard-2023-224437.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00549-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00549-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T16:03:59Z","timestamp":1754409839000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00549-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00549-0","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}